Alizyme
CompanyUnited Kingdom
Alizyme develops one asset, in phase 2, no development reported (cetilistat in obesity). Mostly small molecule acting on LIPF and PNLIP; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 2, no development reported
- 3
- Trials
- 0
- Signals
Pipeline
1Inhibits gastrointestinal lipases, reducing dietary fat absorption and increasing fecal fat excretion.
Phase 2, no development reported, Small molecule, LIPF, PNLIP, obesity, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials3
- Similar companies6